{
    "nct_id": "NCT00561392",
    "title": "A 24-week, Multi-center, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (MMSE10-26)",
    "status": "COMPLETED",
    "last_update_time": "2012-04-10",
    "description_brief": "This study evaluated the safety and efficacy of 10 cm\\^2 rivastigmine patch in patients with Alzheimer Disease (MMSE 10-26). The primary objective was the percentage of patients who stayed on the target size of 10 cm\\^2 for at least 8 weeks. This proportion was then compared to historical data of the percentage of patients who could reach a rivastigmine capsule target dose of 12 mg and stay on it at least 8 weeks.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE4"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "Rivastigmine 5 and 10 cm^2 Patch",
                    "description": "For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm\\^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm\\^2 patch, with adjustments as necessary for safety and tolerability."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "208"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "155"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "53"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "38"
                                }
                            ]
                        },
                        {
                            "type": "Lack of Efficacy",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                }
                            ]
                        },
                        {
                            "type": "Protocol Violation",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "8"
                                }
                            ]
                        },
                        {
                            "type": "Administrative problems",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "4"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Rivastigmine 5 and 10 cm^2 Patch",
                    "description": "For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm\\^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm\\^2 patch, with adjustments as necessary for safety and tolerability."
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "208"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "74",
                                            "spread": "7.7"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "110"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "98"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "Germany",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "208"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Percentage of Participants Treated by Rivastigmine 10 cm^2 Patch for at Least 8 Weeks Who Completed the Study",
                    "description": "Dosages of study medication prescribed to and taken by the patient was assessed in a \"Drug Administration Record\" with start date, end date, dosage and reason for dose adjustment (if applicable). Data was amended by counting the returned medication at the study visits and information by the caregiver.",
                    "populationDescription": "The Intent-to-Treat (ITT) population was defined as all randomized patients who were administered at least one dose of study medication and were assessed at baseline and post-baseline for efficacy at least 1 time.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "Percentage of participants",
                    "timeFrame": "Baseline to Week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine 5 and 10 cm^2 Patch",
                            "description": "For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm\\^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm\\^2 patch, with adjustments as necessary for safety and tolerability."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "182"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "74.2",
                                            "lowerLimit": "67.8",
                                            "upperLimit": "80.5"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Mean Change From Baseline in the Mini-Mental State Examination (MMSE) Score at Week 24",
                    "description": "The MMSE is a brief, practical screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement.",
                    "populationDescription": "The Intent-to-Treat (ITT) population was defined as all randomized patients who were administered at least one dose of study medication and were assessed at baseline and post-baseline for efficacy at least 1 time.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Units on a scale",
                    "timeFrame": "Baseline and Week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine 5 and 10 cm^2 Patch",
                            "description": "For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm\\^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm\\^2 patch, with adjustments as necessary for safety and tolerability."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "182"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.3",
                                            "spread": "3.8"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Mean Change From Baseline in the Trail-making Test Part A Score at Week 24",
                    "description": "The Trail-making test is a neuropsychological test of visual attention and task switching. The task requires a subject to 'connect-the-dots' of 25 consecutive numbers (1,2,3, etc.) on a sheet of paper or computer screen. The goal of the subject is to finish the test as quickly as possible, and the time taken to complete the test is used as the primary performance metric (in seconds). The maximum time allowed is 300 seconds. A negative change score indicates improvement.",
                    "populationDescription": "The Intent-to-Treat (ITT) population was defined as all randomized patients who were administered at least one dose of study medication and were assessed at baseline and post-baseline for efficacy at least 1 time.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Seconds",
                    "timeFrame": "Baseline to Week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine 5 and 10 cm^2 Patch",
                            "description": "For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm\\^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm\\^2 patch, with adjustments as necessary for safety and tolerability."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "182"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-8.9",
                                            "spread": "109.45"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Mean Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score at Week 24",
                    "description": "The ADCS-ADL scale is composed of 23 items developed to assess a patient's performance of both basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, as well as making judgments and decisions. Responses for each item will be obtained from the caregiver through an interview. The range for the total ADCS-ADL score is 0 to 78; a higher score indicates a more self-sufficient individual. A positive change score indicates improvement.",
                    "populationDescription": "The Intent-to-Treat (ITT) population was defined as all patients who were administered at least one dose of study medication and were assessed for efficacy at least 1 time.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Units on a scale",
                    "timeFrame": "Baseline to Week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine 5 and 10 cm^2 Patch",
                            "description": "For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm\\^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm\\^2 patch, with adjustments as necessary for safety and tolerability."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "182"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.3",
                                            "spread": "12.02"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) at Week 24 Assessed by the Physician",
                    "description": "The ADCS-CGIC is an assessment tool to make a judgment of change in a patient's condition. Change is derived from comparing an assessment performed at baseline versus an assessment at the end of the study. Change is categorized into 1 of 7 categories: No change; minimal, moderate, or marked improvement; or minimal, moderate, or marked decline. Results are reported as number of patients in the indicated change category.",
                    "populationDescription": "The Intent-to-Treat (ITT) population was defined as all randomized patients who were administered at least one dose of study medication and were assessed at baseline and post-baseline for efficacy at least 1 time.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "Baseline to Week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine 5 and 10 cm^2 Patch",
                            "description": "For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm\\^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm\\^2 patch, with adjustments as necessary for safety and tolerability."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "182"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "No change",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "47"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Minimal improvement",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "25"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Moderate improvement",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Marked improvement",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "15"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Minimal decline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "37"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Moderate decline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "12"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Marked decline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "5"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Mean Change From Baseline in the Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (ADCS-CGIC) at Week 24 Assessed by the Caregiver",
                    "description": "The ADCS-CGIC is an assessment tool to make a judgment of change in a patient's condition. Change is derived from comparing an assessment performed at baseline versus an assessment at the end of the study. Change is categorized into 1 of 7 categories: No change; minimal, moderate, or marked improvement; or minimal, moderate, or marked decline.",
                    "populationDescription": "The Intent-to-Treat (ITT) population was defined as all randomized patients who were administered at least one dose of study medication and were assessed at baseline and post-baseline for efficacy at least 1 time.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "Baseline t0 Week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine 5 and 10 cm^2 Patch",
                            "description": "For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm\\^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm\\^2 patch, with adjustments as necessary for safety and tolerability."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "182"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "No change",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "21"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Minimal improvement",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Moderate improvement",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "16"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Marked improvement",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "15"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Minimal decline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "56"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Moderate decline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "20"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Marked decline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "14"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Percentage of Participants Treated by Rivastigmine 10 cm^2 Patch for at Least 8 Weeks Regardless Whether They Completed the Study",
                    "description": "Dosages of study medication prescribed to and taken by the patient was assessed in a \"Drug Administration Record\" with start date, end date, dosage and reason for dose adjustment (if applicable). Data was amended by counting the returned medication at the study visits and information by the caregiver.",
                    "populationDescription": "The Intent-to-Treat (ITT) population was defined as all randomized patients who were administered at least one dose of study medication and were assessed at baseline and post-baseline for efficacy at least 1 time.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "Percentage of participants",
                    "timeFrame": "Baseline to Week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine 5 and 10 cm^2 Patch",
                            "description": "For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm\\^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm\\^2 patch, with adjustments as necessary for safety and tolerability."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "182"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "80.8",
                                            "lowerLimit": "75.0",
                                            "upperLimit": "86.5"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Percentage of Participants Who Were Compliant to the 10 cm^2 Patch",
                    "description": "Dosages of study medication prescribed to and taken by the patient was assessed in a \"Drug Administration Record\" with start date, end date, dosage and reason for dose adjustment (if applicable). Data was amended by counting the returned medication at the study visits and information by the caregiver.",
                    "populationDescription": "The Intent-to-Treat (ITT) population was defined as all randomized patients who were administered at least one dose of study medication and were assessed at baseline and post-baseline for efficacy at least 1 time.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Percentage of participants",
                    "timeFrame": "Baseline to Week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine 5 and 10 cm^2 Patch",
                            "description": "For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm\\^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm\\^2 patch, with adjustments as necessary for safety and tolerability."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "182"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "95.0",
                                            "spread": "28.3"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Mean Change From Baseline in the Mini-Zarit Inventory Score of Caregiver Burden at Week 24",
                    "description": "The Mini-Zarit Inventory assesses the burden of a caregiver in caring for a patient. The inventory is composed of 5 questions which are rated according to the following answers: 0 = never, \u00bd = sometimes, 1 = often. The ratings on the 5 questions are added together resulting in a total score of 0 to 7 with a higher score indicating greater caregiver burden. A negative change score indicates reduced burden.",
                    "populationDescription": "The Intent-to-Treat (ITT) population was defined as all randomized patients who were administered at least one dose of study medication and were assessed at baseline and post-baseline for efficacy at least 1 time.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Units on a scale",
                    "timeFrame": "Baseline to Week 24",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine 5 and 10 cm^2 Patch",
                            "description": "For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm\\^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm\\^2 patch, with adjustments as necessary for safety and tolerability."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "182"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.4",
                                            "spread": "1.58"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Rivastigmine 5 and 10 cm^2 Patch",
                    "description": "For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm\\^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm\\^2 patch, with adjustments as necessary for safety and tolerability.",
                    "seriousNumAffected": 18,
                    "seriousNumAtRisk": 208,
                    "otherNumAffected": 49,
                    "otherNumAtRisk": 208
                }
            ],
            "seriousEvents": [
                {
                    "term": "Bradycardia",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Death",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Fatigue",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Malaise",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Bronchitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Femoral neck fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Blood glucose abnormal",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Dehydration",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Back pain",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Brain neoplasm",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Cerebrovascular accident",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Cognitive disorder",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Dementia Alzheimer's type",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Dysstasis",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Grand mal convulsion",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Syncope",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Aggression",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Confusional state",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Disorientation",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Psychotic disorder",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Incontinence",
                    "organSystem": "Renal and urinary disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Circulatory collapse",
                    "organSystem": "Vascular disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Deep vein thrombosis",
                    "organSystem": "Vascular disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Hypertensive crisis",
                    "organSystem": "Vascular disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 208
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 21,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Vomiting",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 15,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Erythema",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 18,
                            "numAtRisk": 208
                        }
                    ]
                },
                {
                    "term": "Pruritus",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "12.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 17,
                            "numAtRisk": 208
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."
            },
            "pointOfContact": {
                "title": "Study Director",
                "organization": "Novartis Pharmaceuticals",
                "phone": "862 778-8300"
            }
        }
    },
    "target_category": "cognitive enhancer",
    "drug": [
        "rivastigmine (Exelon patch, 10 cm^2 \u2248 9.5 mg/24h)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The intervention is rivastigmine delivered via a 10 cm^2 transdermal patch (\u22489.5 mg/24 h). Rivastigmine is a cholinesterase inhibitor that increases acetylcholine and is used to improve cognitive symptoms in Alzheimer disease rather than to alter underlying pathology. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "Act: Key trial details \u2014 24-week, multicenter evaluation of the once-daily 10 cm^2 rivastigmine patch in probable AD (MMSE 10\u201326); the primary outcome was tolerability/ability to stay on the 10 cm^2 patch for \u22658 weeks, and prior trials show the 10 cm^2 patch produced cognitive benefit versus placebo and was non-inferior to capsules. These facts identify the drug as a symptomatic cognitive enhancer. \ue200cite\ue202turn0search1\ue202turn0search6\ue201",
        "Reflect: Classification check \u2014 fits the definition of 'Cognitive enhancer' (improves cognition via cholinergic augmentation; not a biologic, not a disease-modifying small molecule targeting amyloid/tau, and not focused on neuropsychiatric/behavioral symptom management). No evidence in the description that this is a disease-modifying agent or a diagnostic procedure, so 'cognitive enhancer' is the appropriate category. \ue200cite\ue202turn0search5\ue202turn0search3\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The intervention is rivastigmine (Exelon patch), a cholinesterase inhibitor that increases acetylcholine by inhibiting acetylcholinesterase and butyrylcholinesterase; this acts on the cholinergic neurotransmitter system to produce symptomatic cognitive benefit rather than to modify amyloid/tau pathology. \ue200cite\ue202turn0search1\ue202turn0search5\ue202turn0search4\ue201",
        "Act: Key trial details (24-week, once-daily 10 cm^2 rivastigmine patch \u22489.5 mg/24 h) identify the drug as a symptomatic cognitive enhancer that targets the cholinergic neurotransmitter system\u2014therefore the best CADRO match is D) Neurotransmitter Receptors. (Patch dosing and formulation information cited). \ue200cite\ue202turn0search6\ue202turn0search2\ue201",
        "Reflect: This classification fits CADRO because rivastigmine\u2019s mechanism is modulation of neurotransmitter activity (cholinergic enhancement) rather than targeting amyloid, tau, inflammation, or other disease-modifying pathways; prior guidance and labels state it does not alter underlying disease course. Thus D) Neurotransmitter Receptors is the appropriate category. \ue200cite\ue202turn0search1\ue202turn0search6\ue201",
        "Web search results (sources used): 1) Medthority / Exelon prescribing/mechanism summary (rivastigmine enhances cholinergic function via reversible cholinesterase inhibition). \ue200cite\ue202turn0search1\ue201 2) StatPearls / NCBI (mechanism: dual AChE and BuChE inhibition; patch formulations and doses listed). \ue200cite\ue202turn0search5\ue201 3) NCBI / LiverTox (clinical use, patch dosing and effects on CNS cholinergic function). \ue200cite\ue202turn0search4\ue201 4) PMC review / pharmacotherapy primer (patch sizes and 9.5 mg/24 h dose; symptomatic effect, not disease-modifying). \ue200cite\ue202turn0search6\ue201 5) Novartis / Exelon Patch product information and safety/approval statements. \ue200cite\ue202turn0search3\ue202turn0search0\ue201"
    ]
}